Getty Images Natera, Inc. ( NTRA ) is a diagnostic company that provides molecular testing services. The company's offerings include oncology, women’s health, and organ health. Its strongest segment is oncology, particularly minimal residual disease monitoring (MRD). In 2025, NTRA implemented new product launches, obtained new Medicare coverages, and advanced its pipeline for early cancer detectio...
Getty Images Natera, Inc. ( NTRA ) is a diagnostic company that provides molecular testing services. The company's offerings include oncology, women’s health, and organ health. Its strongest segment is oncology, particularly minimal residual disease monitoring (MRD). In 2025, NTRA implemented new product launches, obtained new Medicare coverages, and advanced its pipeline for early cancer detection. Additionally, the company acquired Foresight Diagnostics, which strengthened the company’s position in lymphoma. And, on balance, I feel the company is well-positioned to grow rapidly with its oncology tests, which is why I ultimately rate the stock a “Buy” at these levels. Molecular Diagnostics Natera, Inc. is a molecular diagnostics company offering genetic testing in oncology, women’s health, and organ health. They were founded back in 2004 and are currently headquartered in Austin, Texas. They also operate from CLIA-certified labs in Austin, San Carlos, California, and Boulder, Colorado. Interestingly, NTRA’s clinical testing volumes have been steadily increasing since 2023, and its business appears healthy as well, which is why I felt it was worthwhile covering them. Source: Natera, Inc. Website. Retrieved March 2026. As a quick overview, NTRA’s main oncology product is called Signatera , which uses circulating tumor DNA (ctDNA). This way, they can find and measure cancer that remains in the body using evaluation of minimal residual disease (MRD) to check for recurrence, and also for treatment monitoring. Other tests include Latitude , a tissue-free MRD test for detecting leftover colorectal cancer. Similarly, NTRA’s Altera is a tumor profiling test to better understand tumor biology and guide treatment, and Empower is another type of hereditary cancer risk test. Empower screens for genes linked to inherited cancer risk, covering over 12 cancer types and up to 81 genes, such as those related to breast, ovarian, uterine, colorectal, gastric, prostate, pancreatic, mel...